Adaptive treatment for HER2-positive breast cancer before surgery
Part of Cancer clinical trials.
This trial tests a personalized approach to chemotherapy before surgery for HER2-positive breast cancer. The treatment is adjusted based on how your tumor responds, aiming to give the right amount of therapy for better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have early-stage or locally advanced breast cancer that can be operated on, with a tumor larger than 2 cm.
- Your tumor is HER2-positive (a specific protein test).
- Your tumor is stage II to IIIc, meaning it hasn't spread to distant organs.
- You agree to provide tumor tissue and blood samples for research.
- You have good organ function, including heart, liver, kidney, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.